Suzuken : Notice Regarding the Revision of Consolidated Financial Results Forecast

April 30, 2024

Press Release SUZUKEN CO., LTD.

Shigeru Asano, President and CEO (Stock Code: 9987)

Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange

Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters

Tel.: [phone]

Notice Regarding the Revision of Consolidated Financial Results Forecast

Suzuken Co., Ltd. (hereinafter, "the Company") hereby announces that the Board of Directors resolved at a meeting held today (April 30, 2024) to revise the forecast of the full year consolidated financial results for the fiscal year ended March 31, 2024, which was announced on November 10, 2023.

1. Revision of Full Year Consolidated Financial Results Forecast

1. Revision of full year consolidated financial results forecast for the year ended March 31, 2024 (April 1, 2023 - March 31, 2024)

				Operating		Ordinary	Net income	Net income
		Net sales			attributable to
			income		income	owners of the	per share
							parent
Previous forecast (A)		Millions of yen		Millions of yen		Millions of yen	Millions of yen	Yen
	2,326,700	24,900	27,900	24,200	292.43
Revised forecast (B)	2,386,400	34,800	38,300	29,000	357.68
Change (B-A)	59,700	9,900	10,400	4,800
Change (%)	2.6	39.8	37.3	19.8
[Reference] Results for the same
period of the previous fiscal year	2,314,828	32,605	36,376	20,345	236.47
(Full Year ended March 31, 2023)

(2) Reason for revision

Net sales are expected to exceed the previously announced forecast, mainly due to the market expansion for oncology drugs and the contributions of new drugs such as specialty drugs, as well as sales of products related to COVID-19 (therapeutic and diagnostic agents, and others) surpassing the Company's assumptions.

Operating income, ordinary income, and net income attributable to owners of the parent are expected to surpass the previously announced forecast as a result of an increase in net sales and our continued efforts to reduce selling, general and administrative expenses, despite increasingly fierce price negotiations with our customers in the pharmaceutical distribution sector.

*The forecast of consolidated financial results listed above has been prepared based on the information available, as of the time of publication of the present document.

The actual results may differ from the forecast figures, due to various factors from hereon.

This is an English translation of a statement written initially in Japanese and is provided for reference purposes only. The Japanese original shall prevail in the event of any discrepancy between this document and the original.